<DOC>
	<DOCNO>NCT02752048</DOCNO>
	<brief_summary>The objective study evaluate efficacy 24-week repeated oral dos TAS-205 patient Duchenne Muscular Dystrophy ( DMD ) exploratory manner .</brief_summary>
	<brief_title>A Phase IIa Study TAS-205 Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne Muscular Dystrophy ( DMD ) common fatal genetic disorder diagnose childhood , affect approximately 1 3,500 life male birth . DMD patient suffer relentless decline muscle strength impairs ability walk breathing , result life wheelchairs loss upper body function . The main objective study evaluate efficacy 24-week repeated oral dos TAS-205 patient DMD exploratory manner . The objective study also evaluate safety , dose-response urinary excretion pharmacodynamic ( PD ) marker 24-week repeated oral dos TAS-205 DMD patient .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Able give inform consent . If applicable , able give inform assent . Phenotypic evidence DMD . Male ≧5 year age . Bodyweight ≧7.5 kg ＜60 kg . Able complete 6MWD test distance least 75 m. Able take tablet . If take oral glucocorticoid significant change total daily dose 6 month enrollment . Any serious drug allergy . A forced vital capacity ( FVC ) &lt; 50 % predict value . Wearing respirator continuously ( except use sleep ) . A left ventricular ejection fraction ( EF ) &lt; 40 % fractional shortening ( FS ) &lt; 25 % echocardiogram . Clinically significant cardiac failure respiratory failure . Ongoing immunosuppressive therapy ( corticosteroid ) . Surgical history plan surgery may affect muscular strength motor function . Any injury may affect muscular strength motor function . With systemic allergic disease chronic inflammatory disease . Previous gene therapy ( exon skipping , stop codon read therapy ) , cellbased therapy , investigational agent .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>